Stimulating Results Signal a New Treatment Option for People Living With Painful Diabetic Neuropathy

J Diabetes Sci Technol. 2022 Jun 30;19322968221099542. doi: 10.1177/19322968221099542. Online ahead of print.


Background: Painful diabetic neuropathy (PDN) is a progressive condition that deprives many patients of quality of life. With limited treatment options available, successful pain management can be difficult to achieve.

Methods: We reviewed results of recent data evaluating high frequency spinal cord stimulation (SCS).

Results: from the SENZA-PDN randomized clinical trial (NCT03228420), the largest such trial to date, demonstrated 10-kHz spinal cord stimulation substantially reduced PDN refractory to conventional medical management along with improvements in health-related quality-of-life measures that were sustained over 12 months. These data supported the recent U.S. Food & Drug Administration (FDA) approval for 10-kHz SCS in PDN patients and contributed to the body of evidence on SCS available to health care professionals managing the effects of PDN.

Conclusion: High frequency spinal cord simulation appears to hold promise in treatment of painful diabetic neuropathy. We look forward to future works in the literature that will further elucidate these promising findings.

Keywords: 10-kHz SCS; diabetes; high-frequency spinal cord stimulation; neuromodulation; painful diabetic neuropathy; randomized clinical trial.